Sa et al. [44] demonstrated that insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)-dependent ERBB2 signaling activation contributes to acquired resistance to TKI of radioiodine-refractory papillary thyroid cancer. Here, ERBB2 is linked to thyroid gland papillary carcinoma.